Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
N. Reinmuth,J. W. Goldman,Y. Chen,K. Hotta,G. Statsenko,M. J. Hochmair,M. Ozguroglu,J. H. Ji,M. C. Garassino,A. Poltoratskiy,F. Verderame,L. Havel,I. Bondarenko,G. Losonczy,N. V. Conev,H. Mann,P. Chugh,T. B. Dalvi,L. Paz-Ares